Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Treasury Shares: 2010-2025

Historic Treasury Shares for Anika Therapeutics (ANIK) over the last 4 years, with Jun 2025 value amounting to $957,338.

  • Anika Therapeutics' Treasury Shares rose 1706.30% to $957,338 in Q2 2025 from the same period last year, while for Jun 2025 it was $957,338, marking a year-over-year increase of 1706.30%. This contributed to the annual value of $836,562 for FY2024, which is 8.45% up from last year.
  • Anika Therapeutics' Treasury Shares amounted to $957,338 in Q2 2025, which was up 297.24% from $241,000 recorded in Q1 2025.
  • Over the past 5 years, Anika Therapeutics' Treasury Shares peaked at $957,338 during Q2 2025, and registered a low of $29,000 during Q3 2023.
  • For the 3-year period, Anika Therapeutics' Treasury Shares averaged around $494,916, with its median value being $506,179 (2023).
  • In the last 5 years, Anika Therapeutics' Treasury Shares crashed by 95.81% in 2023 and then surged by 1,706.30% in 2025.
  • Over the past 5 years, Anika Therapeutics' Treasury Shares (Quarterly) stood at $412,658 in 2021, then spiked by 63.67% to $675,405 in 2022, then climbed by 14.21% to $771,358 in 2023, then increased by 8.45% to $836,562 in 2024, then spiked by 1,706.30% to $957,338 in 2025.
  • Its last three reported values are $957,338 in Q2 2025, $241,000 for Q1 2025, and $836,562 during Q4 2024.